TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02479581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: 1. Routine bowel preparation;~2. Liquid food eating 2 days before the operation;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: 1. Induction use Sufentanil 0.5\~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2\~0.6mg/kg,Midazolam0.05\~0.1mg/kg ;~2. Maintain use Sufentanil 1\~2ug/kg·h, Propofol 4\~12mg/kg·h, Sevoflurane 1\~3(minimal alveolar concentration)， Vecuronium 0.06\~0.12mg/kg·h;
Study: NCT01691716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tendoactive
Description: Food supplement containing mucopolysaccharides, type I collagen and vitamin C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tendoactive
Description: Food supplement containing mucopolysaccharides, type I collagen and vitamin C

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric training
Description: Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric training
Description: Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
Study: NCT02577939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Exercise Training (IET)
Description: This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
Study: NCT01441284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pramipexole
Description: pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
Study: NCT02545686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breath hold assessment with CPAP
Description: While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
Study: NCT01441284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03675685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCH (collagenase clostridium histolyticum)
Description: A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
Study: NCT01441284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03651934

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal iron
Description: The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
Study: NCT02479581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: Intravenous infusion of dexamethasone 20mg during the surgery
Study: NCT04310267

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Petit typeface mask
Description: (Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Petit typeface mask
Description: (Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
Study: NCT04147637

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre with MiaoMiao
Description: Use of FreeStyle Libre with MiaoMiao Bluetooth adjunct and mobile device application to enable calibration and alarms
Study: NCT04310267

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Petit typeface mask
Description: (Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
Study: NCT04147637

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre alone
Description: Use of standard FreeStyle Libre with Libre Link app and mobile phone scanning
Study: NCT01281436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HeartSmartKids & Web-based Provider Training
Description: The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
Study: NCT01943136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: papaya 1% extract ointment
Study: NCT01281436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web-based Provider Training
Description: The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.

Intervention type: OTHER
Group type: OTHER
Intervention: Web-based Provider Training
Description: The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
Study: NCT04464031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic alert
Description: The e-alert system was developed by the divisions of Nephrology and Information Management of Guangdong Provincial People's Hospital (Patent Application 201610001950.5). The alert system made a diagnosis of acute kidney injury according to Kidney Disease: Improving Global Outcomes criteria. Then, the doctor receives an alert of acute kidney injury.
Study: NCT00808834

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon A contact lens
Description: Investigational, silicone hydrogel, spherical, soft contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon A contact lens
Description: Investigational, silicone hydrogel, spherical, soft contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lens
Description: Commercially marketed, silicone hydrogel, spherical, soft contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lens
Description: Commercially marketed, silicone hydrogel, spherical, soft contact lens
Study: NCT02479581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: Intravenous infusion of flucloxacillin sodium 1g before the operation
Study: NCT04424056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra +/- Ruxolitinib (stages 2b/3)
Description: administration of Anakinra +/- ruxolitinib, depending of evolution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra and Ruxolitinib (Advanced stage 3)
Description: administration of Anakinra and ruxolitinib
Study: NCT01943136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mupirocin 2% ointment
Study: NCT00476190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Prophase: Intravenously on days 1-3. Induction: Intrathecal on days 15 or 18. Consolidation IB: Intravenously or subcutaneous on days 2-5 and 9-12. Consolidation IC: Intravenously every 12 hours starting on day 1 CNS Therapy: Intrathecal 4 times over 2 weeks. Consolidation II: Intrathecal once every 18 weeks Continuation: Intrathecal every 18 weeks
Study: NCT04424056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab +/- ruxolitinib (stages 2b/3)
Description: administration of Tocilizumab +/- ruxolitinib, depending of evolution
Study: NCT01212822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT04424056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab and Ruxolitinib (Advanced stage 3)
Description: administration of Tocilizumab and Ruxolitinib

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Treatment with drugs or procedures in routine clinical practice
Study: NCT01341691

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
Study: NCT01212822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00539812

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Standard 40 hour state mandated batterer intervention program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Alcohol Intervention combined with standard care
Description: Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
Study: NCT02326506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VA-ELS pump speed variations
Description: Small variations in the pump speed of the veno-arterial extracorporeal life support (VA-ELS) pump
Study: NCT03963466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Oral tranexamic acid group(menstrual period\>2days) 250mg bid（exclude menstrual period ）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Oral tranexamic acid group(menstrual period\>2days) 250mg bid（exclude menstrual period ）
Study: NCT01341691

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chewing gum
Description: single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
Study: NCT03963466

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1064-nm Q-Switched fractional laser
Description: Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 left side of cheek is selected to be treated with 1064-nm Q-Switched fractional laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1064-nm Q-Switched fractional laser
Description: Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 left side of cheek is selected to be treated with 1064-nm Q-Switched fractional laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1064-nm Q-Switched laser
Description: Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 right side of cheek is selected to be treated with 1064-nm Q-Switched laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1064-nm Q-Switched laser
Description: Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 right side of cheek is selected to be treated with 1064-nm Q-Switched laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
Study: NCT01292213

Intervention type: PROCEDURE
Intervention: Cough swab
Description: Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.

Intervention type: PROCEDURE
Intervention: Cough swab
Description: Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.

Intervention type: PROCEDURE
Intervention: Oropharyngeal swab
Description: Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
Study: NCT00476190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Prophase: Intravenously on days 1-3. Induction: Intrathecal on days 15 or 18. Consolidation IB: Intravenously or subcutaneous on days 2-5 and 9-12. Consolidation IC: Intravenously every 12 hours starting on day 1 CNS Therapy: Intrathecal 4 times over 2 weeks. Consolidation II: Intrathecal once every 18 weeks Continuation: Intrathecal every 18 weeks
Study: NCT01393886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Greater Curvature Plication (LGCP)
Description: This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
Study: NCT01249573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascia therapy or transcutaneous fibrolysis
Description: fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fascia therapy or transcutaneous fibrolysis
Description: fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascia therapy or transcutaneous fibrolysis
Description: fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
Study: NCT04409483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir-Ritonavir Drug Combination
Description: 400mg/100mg taken orally twice daily for 14 days.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily
Study: NCT00476190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).~Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).~Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Induction: Intravenously on days 4, 11, 18, 25. Consolidation IA: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Induction: Intravenously on days 4, 11, 18, 25. Consolidation IA: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously on day 1 of each cycle.
Study: NCT01292213

Intervention type: PROCEDURE
Intervention: Oropharyngeal swab
Description: Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.

Intervention type: PROCEDURE
Intervention: Nasopharyngeal swabs
Description: Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.

Intervention type: PROCEDURE
Intervention: Nasopharyngeal swabs
Description: Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.

Intervention type: PROCEDURE
Intervention: Bronchoscopy/ bronchoalveolar lavage samples
Description: Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.

Intervention type: PROCEDURE
Intervention: Bronchoscopy/ bronchoalveolar lavage samples
Description: Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire completion.

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire completion.
Study: NCT03883828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate solution
Description: Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
Study: NCT00476190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Consolidation IB: Intravenously on day 1
Study: NCT03883828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin Ointment
Description: Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
Study: NCT00476190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Consolidation IB: Intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: Prophase: Intravenously on days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: Prophase: Intravenously on days 1-3
Study: NCT04409483

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily
Study: NCT03140371

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High energy high protein peptide feed study
Description: Each patient will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) .
Study: NCT01115478

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: Daily oral dose of 2500 IU from enrollment until delivery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: Daily oral dose of 2500 IU from enrollment until delivery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Daily oral dose of 25 mg from enrollment until delivery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Daily oral dose of 25 mg from enrollment until delivery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose from enrollment until delivery
Study: NCT02886624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir
Description: Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks